Moderna, Merck’s skin cancer vaccine shows rise in survival rates
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Moderna’s mRNA vaccine candidate in combination with Merck Co.’s, therapy, Keytruda, showed greater survival rates and efficacy in patients with skin cancer or.
HQ Team May 13, 2024: Merck has discontinued another cancer experimental immunotherapy treatment in patients with a severe form of melanoma due to.
HQ Team February 17, 2024: Iovance Biotherapeutics, a San Carlos, California-based company, has been given the nod for its T-cell therapy to treat.